Compared to the normal group, M1 markers (MCP-1, CD32) in the AD group increased by 71% and 143%, respectively, whereas M2 markers (TGF-β, Arg-1) decreased by 43% and 48%. This evidence concerns the gene CCL2 and Alzheimer disease.